

**Supplementary table: Normal vs low stiffness index among PHIVA – (based on our controls as a reference to define normal vs low SI)**

	Normal SI (n=355)	Low SI (n=52)	p value
<b>Demographics</b>			
Age*, years	14.0 (12.8-15.1)	14.2 (12.3-16.4)	0.17
Female (n,%)	179 (50.4)	26 (50.0)	0.96
African (n,%)	331 (93.2)	49 (94.2)	0.79
<b>Growth Measures</b>			
Height z score <sup>\$</sup>	-1.3 (1.0)	-1.6 (1.1)	0.05
BMI z score <sup>\$</sup>	0.15 (1.2)	-0.41 (1.2)	0.17
Waist circumference* (cm)	66 (62-71)	67 (62-70)	0.97
Mid-thigh circumference* (cm)	39 (36-42)	39 (36-41)	0.97
Mid upper arm circumference* (cm)	22 (20-24)	22 (20-24)	0.78
<b>Tanner stage</b>			
Prepubertal (Tanner stage 1)	56 (16.2)	9 (18.0)	0.65
Early Puberty (Tanner stage 2 - 3)	134 (38.8)	22 (44.0)	
Late Puberty (Tanner stage 4 - 5)	155 (44.9)	19 (38.0)	
<b>Laboratory measures</b>			
Calcium* (mmol/L)	2.4 (2.3-2.5)	2.4 (2.4-2.5)	0.51
Inorganic Phosphate* (mmol/L)	1.4 (1.3-1.6)	1.5 (1.2-1.6)	0.83
Magnesium* (mmol/L)	0.8 (0.8-0.9)	0.8 (0.8-0.9)	0.50
Alkaline phosphatase* (U/L)	292 (199-379)	237 (182.5-332.5)	0.04
<b>Viral Load, copies/ml (n, %)</b>			
<50	223 (64.8)	24 (47.1)	0.01
≥50 copies/ml	121 (35.2)	27 (52.9)	

<b>CD4 count, cells/uL (n, %)</b>			
≤499	68 (19.4)	16 (31.4)	0.05
≥500	282 (80.6)	35 (68.6)	
<b>WHO HIV staging (n,%)</b>			
Stage I-II	55 (16.1)	5 (9.8)	0.25
Stage III-IV	287 (83.9)	46 (90.2)	
<b>Age at initiation of ARVs (n,%)</b>			
0-5 years	233 (66.2)	37 (72.6)	0.37
6-14 years	119 (33.8)	14 (27.4)	
<b>Age at initiation of ARVs* (years)</b>	4.2 (1.9-7.2)	4.1 (1.5-7.7)	0.69
<b>Duration on ARVs* (years)</b>	9.7 (6.8-11.3)	10.5 (7.2-11.8)	0.22
<b>Current ARV regimen (n, %)</b>			
2 NRTI + NNRTI	204 (57.5)	22 (42.3)	0.12
2 NRTI + PI	114 (32.1)	22 (42.3)	
Others	37 (10.4)	8 (15.4)	
<b>Current use of TDF (n, %)</b>			
Yes	47 (13.2)	6 (11.5)	0.73
<b>Ever use of TDF (n, %)</b>			
Yes	49 (13.8)	6 (11.5)	0.66
<b>Current use of EFV (n, %)</b>			
Yes	204 (57.5)	23 (44.2)	0.07

<b>Ever use of EFV (n, %)</b>			
Yes	282 (79.4)	33 (63.5)	<b>0.01</b>
<b>Current use of LPV/r (n, %)</b>			
Yes	118 (33.2)	25 (48.1)	<b>0.04</b>
<b>Ever use of LPV/r (n, %)</b>			
Yes	175 (49.3)	35 (67.3)	<b>0.02</b>

Legend: \*Median and interquartile range. \$Mean and Standard deviation; ART= antiretroviral therapy; BMI = body mass index; EFV= Efavirenz; LPV/r= Lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI= protease inhibitor; TDF= tenofovir.